Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Johnson & Johnson leads $28 million round in Israel’s V-Wave

V-Wave’s device for treating chronic symptomatic heart failure has been successfully implanted in 30 patients.

Health Israel - V-WAVE

 

Israeli startup V-Wave has completed a $28 million fund raising round. The round was led by Johnson & Johnson Innovation – JJDC Inc. Other participants were TriVentures, Pura Vida and BioStar Ventures. Eli and Nir Barkat’s BRM fund, Pontifax and Edwards Lifesciences, which were already shareholders in V-Wave, also participated.

V-Wave says the funds will support clinical evaluation and development, addition of senior management and manufacturing scale-up of V-Wave’s proprietary minimally invasive device for use in patients with chronic symptomatic heart failure (HF). The shunt is intended to relieve symptoms, improve quality of life, and to reduce the need for acute hospitalization due to worsening episodes of HF in patients who become symptomatic at minimal levels of activity.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.

Each year there are more than one million hospitalizations with acutely worsening HF in the US alone. Direct costs of HF exceed $30 billion, most of which goes for in-patient care. The number of patients with HF is expected to double during the next two decades as baby boomers age and develop heart disease.

As an implanted product, V-Wave’s device has a complicated regulatory path, and so the first implant in a human being that the company announced in April 2014, by Prof. Ran Kornowski, director of the Cardiology Department at Rabin Medical Center, Beilinson Hospital, was an important milestone for it. The company says that, to date, more than thirty patients have been successfully treated.

V-Wave was founded by Yaacov Nitzan, Dr. Gad Keren, and Dr. Ascher Shmulewitz. It raised $7.5 million from Edwards Lifesciences (which is where Nitzan came from), BRM, and Pontifax, and Shmulewitz also invested.

V-Wave CEO Dr. Neal Eigler said, “With the backing of our new and prior investors, we can now accelerate development and clinical evaluation of a new therapy applicable for a large segment of HF patients who need additional treatment options. Together with company President Erez Rozenfeld, we are building a team with the potential to make V-Wave’s unidirectional shunt achieve the data and milestones needed for regulatory approvals and commercialization in the U.S. and around the world.”

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.